The Multiple Faces of Lung Adenocarcinoma: Challenges in Diagnosis DOI Open Access

Ancuţa Alina Constantin,

Andrei Antonio Cotea,

Florin Mihălţan

и другие.

Internal Medicine, Год журнала: 2023, Номер 20(3), С. 69 - 80

Опубликована: Окт. 1, 2023

Abstract Lung cancer dominates the current picture of malignancies worldwide, remaining a tragic first place in mortality statistics. Despite continuous improvements lung screening, refinement surgical techniques, and innovations oncological treatments, remains main contributor to fatalities among all forms neoplastic conditions. (1,2) adenocarcinoma is not just one most common histological types but also deadliest high heterogeneity. Smoking worldwide due its late diagnosis tobacco risk factors for any cancer, including adenocarcinoma, there are other that can increase risk, such as family history professional exposure noxious agents silica, asbestos, radon, heavy metals, diesel fumes . (3) Therefore, through this case series report authors attempt present their experience with three cases broad range differences past medical history, living work conditions, vicious habits smoking. This paper strives establish potential faces adopt, disguising itself under umbrella many parenchymal syndromes, mimicking non-malignant processes, often displaying features very similar an infection, misdiagnosed pneumonia, thereby delaying diagnosis. Additionally, we provide brief synthesis best resources available adenocarcinoma-specific literature, importance distinguishing early signs symptoms, imaging, differential diagnosis, treatment.

Язык: Английский

Transcriptome‐level discovery of survival‐associated biomarkers and therapy targets in non‐small‐cell lung cancer DOI Creative Commons
Balázs Györffy

British Journal of Pharmacology, Год журнала: 2023, Номер 181(3), С. 362 - 374

Опубликована: Окт. 3, 2023

Abstract Background and Purpose Survival rate of patients with lung cancer has increased by over 60% in the recent two decades. With longer survival, identification genes associated survival emerged as an issue utmost importance to uncover most promising biomarkers therapeutic targets. Experimental Approach An integrated database was set up combining multiple independent datasets clinical data transcriptome‐level gene expression measurements. Univariate multivariate analyses were performed identify higher levels linked shorter survival. The strongest filtered include only those known druggability. Key Results entire includes 2852 tumour specimens from 17 cohorts. Of these, 2227 have overall 1256 samples progression‐free time. significant MIF , UBC B2M adenocarcinoma ANXA2 CSNK2A2 KRT18 squamous cell carcinoma. We also aimed reveal best druggable targets non‐smokers cancer. three hits this cohort MDK THY1 PADI2 . established added Kaplan–Meier plotter ( https://www.kmplot.com ) enabling validation future expression‐based both present yet unexamined subgroups patients. Conclusions Implications In study, we a comprehensive for can be utilized rank different subtypes

Язык: Английский

Процитировано

149
Lung Cancer in Women: The Past, Present, and Future DOI Creative Commons
Narjust Florez, Lauren Kiel, Ivy Riano

и другие.

Clinical Lung Cancer, Год журнала: 2023, Номер 25(1), С. 1 - 8

Опубликована: Окт. 20, 2023

Lung cancer is the leading cause of death for women in multiple countries including United States. Women are exposed to unique risk factors that remain largely understudied such as indoor pollution, second-hand tobacco exposure, biological differences, gender differences tolerability and response therapy lung cancer, societal roles, create distinct survivorship needs. continue lack representation clinical trials typically treated with data generated from majority male patient study populations, which may be inappropriate extrapolate generalize females. Current treatment screening guidelines do not incorporate sex-specific physicians also often account when choosing treatments or discussing To best provide targeted approaches, greater further research necessary. Clinicians should understand consequences associated women; thus, a holistic approach acknowledges environmental

Язык: Английский

Процитировано

19
Safety and efficacy of immune checkpoint inhibitor rechallenge in advanced non-small cell lung cancer: a retrospective study DOI Creative Commons

Jia Feng,

Xinyi Chen,

Jiayan Wei

и другие.

Scientific Reports, Год журнала: 2024, Номер 14(1)

Опубликована: Янв. 28, 2024

We conducted a retrospective study to evaluate the efficacy of immune checkpoint inhibitor (ICI) rechallenge in patients with advanced non-small cell lung cancer (NSCLC). The included 111 who had previously received ICI therapy and experienced disease progression. primary endpoints assessed were overall survival (OS), progression-free (PFS), objective response rate (ORR). Our findings revealed that showed promising results improving patient outcomes. OS (r) is time from rechallenging inhibitors last follow-up or death any cause. median was 14.3 months (95% CI 11.3-17.3 months), PFS 5.9 4.1-7.7 months). ORR 17.1%; DCR 82.3%. Subgroup analysis demonstrated without brain liver metastases longer compared those (21.6 vs. 13.8 months, χ2 = 3.873, P 0.046; 20.8 9.1 10.733, 0.001, respectively). Moreover, driver gene mutations exhibited significantly than wild-type (22.9 16.1 7.5 10.710, 0.005). Notably, switched different during shorter did not change medications (10.4 21.1 9.014, 0.003). incidence immune-related adverse events differ between two treatment phases. These suggest may be viable therapeutic strategy for select NSCLC patients. Further prospective studies are needed validate these guide decisions NSCLC.

Язык: Английский

Процитировано

6
Prevalence of EGFR Mutations in Patients With Resected Stage I-III NSCLC: Results From the EARLY-EGFR Study DOI Creative Commons
Ross A. Soo, Thanyanan Reungwetwattana, Herman Andrés Perroud

и другие.

Journal of Thoracic Oncology, Год журнала: 2024, Номер unknown

Опубликована: Июнь 1, 2024

Background:There is limited literature on the prevalence of EGFR mutations in early-stage non-small cell lung cancer (NSCLC).EARLY-EGFR (NCT04742192), a cross-sectional study, determined NSCLC. Methods:This non-interventional, real-world study enrolled consecutive patients with resected stage IA-IIIB (American Joint Committee Cancer 8 th edition) NSCLC from 14 countries across Asia, Latin America, and Middle East Africa.The primary endpoint was secondary endpoints included mutation subtypes treatment patterns. Results :Of 601 (median [range] age: 62.0 [30.0-86.0]years) enrolled, 52.7% were females 64.2% non-smokers.The majority had IA-IB (64.1%) adenocarcinoma histology (98.7%).Overall 51.0%; reported exon-19 deletions (48.5%) followed by exon-21 L858R (34.0%).Women higher rate than men (64.0%versus 36.4%).Compared no mutations, more likely to be non-smokers (35.1% versus 60.9%) have I compared II III (54.8% 47.3% 35.6%).Systemic adjuvant therapy planned 33.8% IB IIIB disease chemoradiotherapy 6.8% patients.Age ≥60 years, females, Asians found significantly (p < 0.05) odds while smoking history lower mutations.J o u r n l P e -p f 5 Conclusion:The EARLY-EGFR provides an overview subtype NSCLC.The highlights adherence guidelines suggesting unmet need for improved therapy.

Язык: Английский

Процитировано

6
Genetic differences between smokers and never-smokers with lung cancer DOI Creative Commons
Piotr Kuśnierczyk

Frontiers in Immunology, Год журнала: 2023, Номер 14

Опубликована: Фев. 2, 2023

Smoking is a major risk factor for lung cancer, therefore cancer epidemiological trends reflect the past of cigarette smoking to great extent. The geographic patterns in mortality closely follow those incidence. Although strongly associated with smoking, only about 15% smokers get and also some never-smokers develop this malignancy. less frequent, never seventh leading cause deaths both sexes worldwide. Lung differs many aspects: histological types, environmental factors representing risk, genes disease. In review, we will focus on genetic differences between versus never-smokers: gene expression, germ-line polymorphisms, mutations, as well ethnic gender differences. Finally, treatment options be briefly reviewed.

Язык: Английский

Процитировано

15
Association Between Depression and Lung Cancer Risk Among Postmenopausal Women DOI Creative Commons
Yuanyuan La, Su Yon Jung, Xiaoyun Liang

и другие.

Cancer Medicine, Год журнала: 2025, Номер 14(5)

Опубликована: Март 1, 2025

In recent years, the association between depression and various chronic diseases has attracted widespread attention. However, effect of on lung cancer incidence not been well studied. This study aimed to explore whether increases analyze mediating moderating roles smoking in this relationship. used large-scale longitudinal data sourced from Women's Health Initiative, encompassing 123,961 postmenopausal women. Depressive symptoms were measured using 8-item Burnam regression algorithm with a cut-point 0.06, was defined as either depressive or antidepressant use at baseline. The relationship examined multivariate Cox proportional hazards model. A four-way decomposition causal mediation approach employed investigate potential effects smoking. After mean follow-up 17.6 3434 cases identified. rate higher among individuals compared those without (HR: 1.15, 95% CI: 1.05-1.26). Cigarette partially mediated incidence, explaining about 27% effect. identified significant mediates highlights that managing may play key role reducing risk decreasing tobacco use. Psychological support should be integrated traditional cessation programs for prevention.

Язык: Английский

Процитировано

0
A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL) DOI Creative Commons
Alessandro Cafaro, Flavia Foca, Oriana Nanni

и другие.

Frontiers in Oncology, Год журнала: 2024, Номер 14

Опубликована: Март 27, 2024

Introduction The phase III Keynote-189 trial established a first-line treatment combining pembrolizumab with pemetrexed and platinum as standard for patients stage IV non-small cell lung cancer (NSCLC) without known EGFR ALK driver mutations independent of programmed death ligand 1 (PD-L1) expression. However, in Italy, eligibility the National Health Service payment program is limited to PD-L1 &lt;50%. PEMBROREAL study assesses real-world effectiveness safety eligible program. Methods retrospective, observational on NSCLC who started combined within reimbursability time window, considered December 2019 2020. primary endpoints were assess progression-free survival (PFS) overall (OS; using Kaplan–Meier method), response therapy, tolerability. Results Until February 2022, 279 (median follow-up: 19.7 months) have been observed. median PFS was 8.0 months (95% confidence interval: 6.5–9.2). OS not reached, but we can estimate 12- 24-month rate treatment: 66.1% 52.5%, respectively. expression Eastern Cooperative Group (ECOG) Performance Status both associated OS. Overall, only 44.4% reported an adverse event, whereas toxicity led 5.4% discontinuation rate. Conclusion results shown that effective metastatic non-squamous NSCLC, even levels below 50%, despite differences patient demographics pathological features compared study. events during more typical chemotherapy rather than immunotherapy, physicians able manage them easily.

Язык: Английский

Процитировано

4
Metabolomics-based search for lung cancer markers among patients with different smoking status DOI Creative Commons

Agnieszka Klupczynska-Gabryszak,

Evangelia Daskalaki, Craig E. Wheelock

и другие.

Scientific Reports, Год журнала: 2024, Номер 14(1)

Опубликована: Июль 4, 2024

Tobacco smoking is the main etiological factor of lung cancer (LC), which can also cause metabolome disruption. This study aimed to investigate whether observed metabolic shift in LC patients was associated with their status. Untargeted metabolomics profiling applied for initial screening changes serum profile between and chronic obstructive pulmonary disease (COPD) patients, selected as a non-cancer group. Differences metabolite profiles current former smokers were tested. Then, targeted methods verify validate proposed biomarkers. For untargeted metabolomics, single extraction-dual separation workflow applied. The samples analyzed using liquid chromatograph-high resolution quadrupole time-of-flight mass spectrometer. Next, metabolites quantified chromatography-triple-quadrupole spectrometry. acquired data confirmed that patients' stratification based on status impacted discriminating ability identified marker candidates. Analyzing validation set enabled us determine if putative markers truly robust. It demonstrated significant differences case four metabolites: allantoin, glutamic acid, succinic sphingosine-1-phosphate. Our research showed studying influence strong environmental factors, such tobacco smoking, should be considered since it reduces risk false positives improves understanding shifts patients.

Язык: Английский

Процитировано

4
Reagentless aptamer based on the ultrasensitive and fast response electrochemical capacitive biosensor for EGFR detection in non-small cell lung cancer DOI
Enkhzaya Ganbold, Nam‐Young Kim, Yu Mi Kim

и другие.

Biosensors and Bioelectronics, Год журнала: 2025, Номер 278, С. 117319 - 117319

Опубликована: Март 7, 2025

Язык: Английский

Процитировано

0
The Lung Microbiome in COPD and Lung Cancer: Exploring the Potential of Metal-Based Drugs DOI Open Access
Megan O’Shaughnessy, Orla Sheils, Anne‐Marie Baird

и другие.

International Journal of Molecular Sciences, Год журнала: 2023, Номер 24(15), С. 12296 - 12296

Опубликована: Авг. 1, 2023

Chronic obstructive pulmonary disease (COPD) and lung cancer 17 are two of the most prevalent debilitating respiratory diseases worldwide, both associated with high morbidity mortality rates. As major global health concerns, they impose a substantial burden on patients, healthcare systems, society at large. Despite their distinct aetiologies, COPD share common risk factors, clinical features, pathological pathways, which have spurred increasing research interest in co-occurrence. One area particular is role microbiome development progression these diseases, including transition from to cancer. Exploring novel therapeutic strategies, such as metal-based drugs, offers potential avenue for targeting improve patient outcomes. This review aims provide an overview current understanding microbiome, emphasis cancer, discuss drugs strategy conditions, specifically concerning microbiome.

Язык: Английский

Процитировано

9